In a report released on December 28, Kaveri Pohlman from BTIG maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $70.00. The company’s shares closed last Friday at $19.10.
According to TipRanks, Pohlman is an analyst with an average return of -11.6% and a 32.50% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Genmab, and Ambrx Biopharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $45.80 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $25.47 and a one-year low of $12.95. Currently, Arcus Biosciences has an average volume of 771.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences (RCUS) Company Description:
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS:
